Table 411

Metabolic Profile of the Control and Experimental Group Patients after Matching for Age, Gender, and Severity of Disease at Two Monthly Intervals (mg/dL, Mean ± SD)

Parameters

Triglyceride Control group Experimental group

Total cholesterol Control group Experimental group HDL-C Control group Experimental group

LDL-C Control group Experimental grp VLDL-C Control Group Experimental group

Non-HDL-C Control group Experimental group TC:HDL-C Control group Experimental group

LDL-C:HDL-C Control group Experimental group ApoA1 Control group Experimental group

ApoB

Control group Experimental group

ApoA1:B Control group Experimental group

Baseline

2 months

4 months

26.4 ± 17.0* 28.5 ± 17.8 23.3 ± 10.0** 23.1 ± 8.5***

132.2 ± 28.0* 133.7 ± 45.4 132.0 ± 34.4 145.1 ± 42.3:

108.8 ± 79.6*** 106.5 ± 79.7 81.3 ± 24.0*** 88.7 ± 43.7***

*p < .05, **p < .01, ***p < .001 vs. baseline.

Spirulina effectively lowered the lipids and lipoprotein fraction in these patients, a significant reduction in the atherogenic indices, that is, TC:HDL-C an LDL-C:HDL-C were also observed. Such changes in the lipid levels have also been associated with a lower incidence of CHD.6

The reduction in the elevated lipid levels led to an improvement in the apo A1:B ratio (p < .001) after 4 months of supplementation in the experimental group (Table 4.11). Spirulina supplementation also showed significant reduction in the apo B levels (p < .001) (Table 4.11) in the experimental group after 4 months of Spirulina supplementation. Thus, this beneficial effect of Spirulina suggests that it helped in decreasing the risk of developing cardiovascular disease in these patients and was also helpful in retarding the further progression of renal disease.

In addition, the supplementation of Spirulina in the experimental group also showed substantial reduction in the number of relapses. On the basis of this the clinician had brought down the level of drug to 54% of the initial requirements where as in the control group, the patients required 87% of the initial level for the treatment of nephrotic syndrome. These observations clearly demonstrate and substantiate that Spirulina had shown a remarkable improvement in the prognosis of nephrotic syndrome patients.

Conclusions

Hence, it can be said that Spirulina aided in improving the quality of the experimental group patients in a better way as compared to the patients in the control group.

Was this article helpful?

0 0
Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook


Post a comment